Ipca Labs, BRL to co-develop next-gen biologics for cancer and autoimmune diseases
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Subscribe To Our Newsletter & Stay Updated